BioCryst Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010

GlobalData, November 2010, Pages: 63

BioCryst Pharmaceuticals, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “BioCryst Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- BioCryst Pharmaceuticals, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of BioCryst Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of BioCryst Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the BioCryst Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate BioCryst Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of BioCryst Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the BioCryst Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with BioCryst Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of BioCryst Pharmaceuticals, Inc. and identify potential opportunities in those areas.

List of Tables
List of Figures
BioCryst Pharmaceuticals, Inc. Snapshot
BioCryst Pharmaceuticals, Inc. Overview
Key Information
Key Facts
BioCryst Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
BioCryst Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
BioCryst Pharmaceuticals, Inc. – Pipeline Products Glance
BioCryst Pharmaceuticals, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
BioCryst Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
BioCryst Pharmaceuticals, Inc. – Drug Profiles
Peramivir
Product Description
Mechanism of Action
R&D Progress
BCX4208
Product Description
Mechanism of Action
R&D Progress
BCX4208 + Allopurinol
Product Description
Mechanism of Action
R&D Progress
forodesine
Product Description
Mechanism of Action
R&D Progress
BioCryst Pharmaceuticals, Inc. – Pipeline Analysis
BioCryst Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
BioCryst Pharmaceuticals, Inc. Pipeline Products By Target
BioCryst Pharmaceuticals, Inc. – Pipeline Products by Route of Administration
BioCryst Pharmaceuticals, Inc. – Pipeline Products by Molecule Type
BioCryst Pharmaceuticals, Inc. – Recent Pipeline Updates
BioCryst Pharmaceuticals, Inc. - Dormant Projects
BioCryst Pharmaceuticals, Inc. – Company Statement
BioCryst Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Nov 08, 2010: BioCryst To Present New Data For BCX4208 Monotherapy At 74th Annual American College Of Rheumatology Scientific Meeting
Sep 16, 2010: BioCryst Reports Positive Results From A Phase II Study Of BCX4208 Combined With Allopurinol In Patients With Gout
Sep 16, 2010: BioCryst Announces Positive Phase II Study Results Of BCX4208 Combined With Allopurinol In Patients With Gout
Sep 15, 2010: BioCryst Announces Results From Two Forodesine Oncology Studies
Sep 15, 2010: BioCryst Announces Results From Two Forodesine Oncology Studies
Sep 15, 2010: BioCryst Announces Results From Two Forodesine Oncology Studies
Aug 16, 2010: BioCryst's Partner Green Cross Receives Marketing And Manufacturing Approval For Peramivir In South Korea
Jun 01, 2010: BioCryst Initiates Phase II Study Of BCX4208 Alone And In Combination With Allopurinol In Patients With Gout
Jun 01, 2010: BioCryst Initiates Phase II Study Of BCX4208 Alone And In Combination With Allopurinol In Patients With Gout
Apr 28, 2010: BioCryst Reports Positive Results From Part One Of Phase IIa Study Of BCX4208 In Patients With Gout
Financial Deals Landscape
BioCryst Pharmaceuticals, Inc., Deals Volume Summary, 2004 to YTD 2010
BioCryst Pharmaceuticals, Inc., Deals Summary By Region, 2004 to YTD 2010
BioCryst Pharmaceuticals, Inc., Deals Summary, 2004 to YTD 2010
BioCryst Pharmaceuticals, Inc. Detailed Deal Summary
Equity Offering
BioCryst Pharmaceuticals Completes Public Offering Of $49 Million
BioCryst Completes Private Placement Of $65.3 Million
BioCryst Pharmaceuticals Completes Private Placement Of $30 Million
BioCryst Pharmaceuticals Completes Private Placement Of $24 Million
BioCryst Pharmaceuticals Completes Private Placement Of $21.43 Million
BioCryst Pharmaceuticals Enters Into Co-Marketing Agreement With Merck Serono
BioCryst Pharmaceuticals Enters Into Co-Marketing Agreement With Hikma Pharmaceuticals
BioCryst Enters Into A Co-Marketing Agreement With NT Pharma
BioCryst Pharmaceuticals Enters Into An Agreement With SCOLR Pharma
BioCryst Pharmaceuticals Enters Into Co-Development Agreement With Green Cross
Mundipharma Enters Into Agreement With BioCryst Pharmaceuticals
Roche Signs An Agreement With BioCryst Pharmaceuticals
Licensing Agreements
Biocryst Pharmaceuticals Amends Licensing Agreement With Shionogi
BioCryst Pharmaceuticals Enters Into Licensing Agreement With Shionogi
BioCryst Pharmaceuticals Terminates Agreement With Roche
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans
• The Future of the Biodefense Industry: Regulation, Funding Opportunities & Company Profiles
• Sports and Fitness Nutrition - Global Strategic Business Report
• eLEARNING - Global Strategic Business Report
• Charter Schools - Global Outlook
• Aerospace and Defense Industry - Global Strategic Business Report
• Education Services - Global Strategic Business Report
• Commercial And Military Flight Simulation - Global Strategic Business Report
• Private Tutoring - Global Strategic Business Report
• Defense Robotics - Global Strategic Business Report